OssDsign AB ((SE:OSSD)) announced an update on their ongoing clinical study.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
The OssDsign® Spine Registry Study, officially titled ‘PROSPECTIVE OBSERVATIONAL SPINE FUSION REGISTRY FOR OssDsign® BONE GRAFT SUBSTITUTES IN REAL WORLD CLINICAL PRACTICE,’ aims to evaluate the clinical outcomes and real-world application of OssDsign® AB’s bone graft substitutes in spine fusion surgeries. This study is significant as it seeks to provide valuable insights into the effectiveness of these substitutes in treating conditions like Degenerative Disc Disease and Spinal Stenosis.
The intervention being tested is the OssDsign® Catalyst, a device described as an osteoconductive, resorbable, porous, 100% nano synthetic calcium phosphate bone void filler. Its intended purpose is to aid in bone regeneration during spine fusion procedures.
The study is designed as a multi-center, prospective, observational cohort study. It does not involve random allocation or masking, focusing instead on observing real-world outcomes in patients undergoing spine fusion surgeries.
Key dates for the study include its start date on March 22, 2022, and the last update submitted on June 3, 2025. These dates are crucial for tracking the study’s progress and ensuring timely updates for stakeholders.
The market implications of this study are significant for OssDsign AB, as positive outcomes could enhance investor confidence and potentially boost the company’s stock performance. The study’s findings may also influence the competitive landscape in the spinal surgery market, where innovation in bone graft substitutes is a key area of interest.
The OssDsign® Spine Registry Study is currently recruiting, with further details available on the ClinicalTrials portal.